Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Austin Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$518,410

379 payments

Through program year 2025, Austin Clinical Research is reported as receiving $518,410 in research payments, across 379 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $468,321 370
2024 Research $2,163 3
2023 Research $271 1
2022 Research $47,655 5

Breakdown

Who paid Research payments · program years 2022–2025
  1. Boehringer Ingelheim International GmbH $452,100 370 payments
  2. Alcon Research LLC $47,926 6 payments
  3. Alexion Pharmaceuticals, Inc. $17,995 1 payment
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $389 2 payments
Studies the money was for Research payments · program years 2022–2025
  1. CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy $443,362 300 payments
  2. A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $32,955 3 payments
  3. A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) $17,995 1 payment
  4. A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $14,700 2 payments
  5. A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. $3,290 36 payments
  6. JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 $2,865 23 payments
  7. BI 764524 Phase 2b $2,024 2 payments
  8. A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema $809 10 payments
  9. A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $271 1 payment
  10. -Ph II (12mo treatment) $139 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record